These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 36649662)

  • 1. Designer benzodiazepines: an update.
    Yu X; Greenblatt HK; Greenblatt DJ
    Expert Rev Clin Pharmacol; 2023 Feb; 16(2):109-117. PubMed ID: 36649662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designer drugs: mechanism of action and adverse effects.
    Luethi D; Liechti ME
    Arch Toxicol; 2020 Apr; 94(4):1085-1133. PubMed ID: 32249347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports.
    Orsolini L; Corkery JM; Chiappini S; Guirguis A; Vento A; De Berardis D; Papanti D; Schifano F
    Curr Neuropharmacol; 2020; 18(9):809-837. PubMed ID: 31933443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An expanding world of new psychoactive substances-designer benzodiazepines.
    Zawilska JB; Wojcieszak J
    Neurotoxicology; 2019 Jul; 73():8-16. PubMed ID: 30802466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and concentrations of new designer stimulants, synthetic opioids, benzodiazepines, and hallucinogens in postmortem hair samples: A 13-year retrospective study.
    Niebel A; Westendorf L; Krumbiegel F; Hartwig S; Parr MK; Tsokos M
    Drug Test Anal; 2022 Jan; 14(1):110-121. PubMed ID: 34435749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New and Emerging Illicit Psychoactive Substances.
    Graddy R; Buresh ME; Rastegar DA
    Med Clin North Am; 2018 Jul; 102(4):697-714. PubMed ID: 29933824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines - an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolam.
    Moosmann B; Bisel P; Franz F; Huppertz LM; Auwärter V
    J Mass Spectrom; 2016 Nov; 51(11):1080-1089. PubMed ID: 27535017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in neuronal activity in rat primary cortical cultures induced by illicit drugs and new psychoactive substances (NPS) following prolonged exposure and washout to mimic human exposure scenarios.
    Zwartsen A; Hondebrink L; Westerink RH
    Neurotoxicology; 2019 Sep; 74():28-39. PubMed ID: 31078573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The blood-to-plasma ratio and predicted GABA
    Manchester KR; Waters L; Haider S; Maskell PD
    Forensic Toxicol; 2022 Jul; 40(2):349-356. PubMed ID: 36454409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Agents of Substance Use/Misuse.
    Michienzi AE; Borek HA
    Emerg Med Clin North Am; 2022 May; 40(2):265-281. PubMed ID: 35461623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel psychoactive substances: the pharmacology of stimulants and hallucinogens.
    Schifano F; Papanti GD; Orsolini L; Corkery JM
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):943-54. PubMed ID: 26985969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2013-2016: A Review.
    Logan BK; Mohr ALA; Friscia M; Krotulski AJ; Papsun DM; Kacinko SL; Ropero-Miller JD; Huestis MA
    J Anal Toxicol; 2017 Sep; 41(7):573-610. PubMed ID: 28459969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of cathinones and other new psychoactive substances in hair of parents and children of families with known or suspected parental abuse of conventional illegal drugs.
    Niebel A; Pragst F; Krumbiegel F; Hartwig S
    Forensic Sci Int; 2022 Feb; 331():111148. PubMed ID: 34923263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature.
    Chiappini S; Mosca A; Miuli A; Santovito MC; Orsolini L; Corkery JM; Guirguis A; Pettorruso M; Martinotti G; Di Giannantonio M; Schifano F
    Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34204131
    [No Abstract]   [Full Text] [Related]  

  • 15. Designer Benzodiazepines: Another Class of New Psychoactive Substances.
    Moosmann B; Auwärter V
    Handb Exp Pharmacol; 2018; 252():383-410. PubMed ID: 30367253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phantom menace: novel psychoactive substances and the UK Armed Forces.
    Hunter AH; Ayres T; Moreland N; Cox A
    J R Army Med Corps; 2018 Nov; 164(6):450-457. PubMed ID: 29934414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significant toxicity following an increase in poisonings with designer benzodiazepines in the Netherlands between 2010 and 2020.
    Essink S; Nugteren-van Lonkhuyzen JJ; van Riel AJHP; Dekker D; Hondebrink L
    Drug Alcohol Depend; 2022 Feb; 231():109244. PubMed ID: 34998250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Emergence of New Psychoactive Substance (NPS) Benzodiazepines. A Survey of their Prevalence in Opioid Substitution Patients using LC-MS.
    Mc Namara S; Stokes S; Nolan J
    Ir Med J; 2019 Aug; 112(7):970. PubMed ID: 31642644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017-2020: A Review.
    Mohr ALA; Logan BK; Fogarty MF; Krotulski AJ; Papsun DM; Kacinko SL; Huestis MA; Ropero-Miller JD
    J Anal Toxicol; 2022 Jul; 46(6):e116-e185. PubMed ID: 35445267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outpatient Treatment of Chronic Designer Benzodiazepine Use: A Case Report.
    Hauck TS; Rochon S; Bahra P; Selby P
    J Addict Med; 2022 Mar-Apr 01; 16(2):e137-e139. PubMed ID: 33900229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.